Hao Zeng

16PUBLICATIONS
9CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Nov 14, 2024
Tertiary lymphoid structures potentially promote immune checkpoint inhibitor response in SMARCB1-deficient medullary renal cell carcinoma.

Yanfeng Tang, Junru Chen, Mengxin Zhang

|Mar 03, 2023
Multidisciplinary Team (MDT) Discussion Improves Overall Survival Outcomes for Metastatic Renal Cell Carcinoma Patients.

Yuhao Zeng, Sha Zhu, Zilin Wang

|Sep 06, 2022
Plasma Exosomal AKR1C3 mRNA Expression Is a Predictive and Prognostic Biomarker in Patients with Metastatic Castration-Resistant Prostate Cancer.

Sha Zhu, Yuchao Ni, Zilin Wang

|Feb 21, 2022
Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world study.

Haoran Zhang, Junru Chen, Xingming Zhang

|Aug 26, 2021
The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.

Zhipeng Wang, Sha Zhu, Jinge Zhao

|Jun 29, 2021
Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate.

Jinge Zhao, Guangxi Sun, Sha Zhu

Pageof 3

Frequent Collaborators

4 joint publications

Ni Chen

3 joint publications

Pengfei Shen

1 joint publications

Sha Zhu

1 joint publications

Haoran Zhang